Quick generic drug approval bulletin for today. If you or a loved one suffers from an enlarged prostate, this is important generic drug news. Watson Pharmaceuticals has announced that it has filed an application with the Food and Drug Administration (FDA) for a generic version of GlaxoSmithKline’s prescription drug Jalyn which benign prostatic hyperplasia in men with an enlarged prostate.
According to the Mayo Clinic, prostate gland enlargement is a common condition as men get older. Also called benign prostatic hyperplasia (BPH) and prostatic hypertrophy, prostate gland enlargement can cause bothersome urinary symptoms. Untreated prostate gland enlargement can block the flow of urine out of the bladder and can cause bladder, urinary tract or kidney problems.
Considering a thirty-day supply of brand-name Jalyn is currently running almost $120, a generic version of Jalyn could easily be a major savings for many prostate patients. Unfortunately, it does look like we may have to wait a bit longer for this one. GlaxoSmithKline has already filed a lawsuit against Watson to block any FDA approval of the generic until its patent expires.
Do you know someone who suffers from an enlarged prostate? Tell us about it!
- Generic Drug News: GlaxoSmithKline Files Lawsuit to Stop Generic Version of Prostate Drug Avodart
- Generic Drug News: Application Filed for Generic Version of Cancer Drug Tykerb
- Generic Drug Alert: FDA Approves Generic Version of Furadantin for Urinary Tract Infection (UTI)
- New Generic Drug Approval: Generic Flomax for BPH
- Generic Drug News: Pfizer Files Lawsuit to Block Generic Version of Pain Drug Lyrica